Abstract
The monoclonal anti-CD33 antibody (gemtuzumab ozogamicin: GO) represents a therapeutic option for leukemic patients with CD33-positive disease. Few reports relate its action in patients with ALL who anomalously express CD33. We here report GDRT, WM, diagnosed at the age of 4 years as having standard-risk ALL, whose immunophenotypic expression included: CD34, HLA-DR, TdT, CD19, CD79a, CD10 and also ectopic presence of the myeloid antigens CD13 and CD33, treated as per the Brazilian Cooperative Protocol-93, including: VCR, DEXA, DAUNO, ASP and ARA-C as induction, high-dose MTX as intensification, maintenance with 6-MP, regular and high-dose MTX and prophylactic intrathecal triple drugs (MADIT: MTX+ ARA-C+ DEXA).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
